The Board of Genscript Biotech Corporation announced that Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang have been appointed as independent non-executive Directors and members of the nomination committee of the Company with effect from 12 April 2024. The biographical details and other information of Mr. Cheung and Dr. Shi are set out below: Mr. Cheung, aged 64, has over 30 years of professional accounting and auditing experience. He has been a member of Hong Kong Institute of Certified Public Accountants since October 1986 and was a member of its disciplinary panel from January 2015 to December 2020.

Mr. Cheung is currently serving as a director in various public companies in Hong Kong and the United States. Mr. Cheung has been an independent non-executive director and chairman of the audit committee of each of JW (Cayman) Therapeutics Co. Ltd. and Hua Medicine, companies the shares of which are listed on The Stock Exchange of Hong Kong Limited since October 2020 and January 2023 respectively.

In addition, Mr. Cheung has been an independent non-executive director and chairman of the audit committee of CanSino Biologics Inc., a company the shares of which are listed on the Hong Kong Stock Exchange and Shanghai Stock Exchange, since February 2024. He is also an independent director and the chairman of audit committee of Adagene Inc., a company the shares of which are listed on Nasdaq Stock Market, since February 2021. From July 2018 to June 2020, Mr. Cheung was the deputy area managing partner of Ernst & Young (EY) in Asia Pacific, overseeing its business operations, finance, information technology and risk management functions.

During the same period, Mr. Cheung was a member of each of the EY Asia Pacific's Area Operating Executives, EY's Global Accounts Committee and EY's Global Markets and Investment Committee. From July 2013 to June 2018, Mr. Cheung was EY's assurance managing partner in Greater China, managing its audit, financial accounting advisory, forensic and climate changes and sustainability services. During that period, he was also a member of EY Greater China's leadership team.

Mr. Cheung's other prior responsibilities with EY include his service as the chief operating officer of EY Hua Ming LLP from July 2011 to June 2013, an assurance partner of EY China from July 2010 to June 2011 and the area chief financial officer of EY Asia Pacific from July 2009 to June 2010. Prior to joining EY in September 2006, Mr. Cheung was an assurance partner with PricewaterhouseCoopers Zhong Tian LLP and an assurance partner with Arthur Andersen in China and Hong Kong successively. Mr. Cheung obtained a bachelor's degree in accounting and finance from the University of Lancaster in the United Kingdom in June 1982, and a master's degree in accounting and finance from London School of Economics in the United Kingdom in August 1983.

Although Mr. Cheung was the former deputy area managing partner at EY, which is the auditor of the Company as at the date of this announcement, before his retirement in June 2020, the Nomination Committee and the Board are of the view that Mr. Cheung has satisfied the independence requirements for independent non-executive Directors under Rule 3.13 of the Listing Rules taking into account the following factors: Mr. Cheung has ceased to be a partner of EY for more than two years immediately prior to his proposed appointment as an independent non-executive Director, throughout his service in EY, Mr. Cheung (a) did not serve as a member or leader of the execution team in providing audit or consulting services to the Company, (b) did not serve as an audit partner or engagement partner of EY in providing services to the Company, and (c) had never been consulted on or involved in providing technical supports related to EY's audit services to the Company, since his retirement from EY, Mr. Cheung has not been involved nor has he participated in any transaction between the Company and EY, and Mr. Cheung has met all of the requirements under Rule 3.13 of the Listing Rules. The Company has demonstrated to the satisfaction of the Hong Kong Stock Exchange that Mr. Cheung is independent and fulfills all independence requirements under Rule 3.13 of the Listing Rules. Dr. Shi, aged 56, has over 30 years of experience in life science research and development, sales and marketing, business development and investment.

Since January 2017, Dr. Shi has been the managing partner of Serica Partners, a China-based venture fund focused on the investment in vitro diagnostics (IVD) and medical devices in China. Dr. Shi has been the chairperson of careLYFE Co. Ltd., since December 2017.

Dr. Shi has been a board member of Guangzhou AnchorDx Medical Co. Ltd., a diagnostics company focused on developing cancer early detection tests, since October 2017. Dr. Shi previously served as executive director and chief executive officer of Adicon International Limited, a leading independent clinical laboratory in China, from October 2018 to April 2019, and from April 2019 to May 2020, respectively.

From February 2017 to March 2019, Dr. Shi served as director and chief executive officer of NuProbe Global Inc., a liquid biopsy technology company which he co-founded. He was the President Asia Pacific of QIAGEN N.V., from October 2005 to February 2015. Prior to joining QIAGEN N.V., Dr. Shi held senior positions at Bridge Pharmaceuticals, GenoSpectra Inc. and A.M. Pappas&Associates, and served as a faculty member at the School of Medicine of National University of Singapore.

Dr. Shi was a founding director of BayHelix Group, and was elected Chairman from January 2017 to January 2019. Dr. Shi has been a member on the Biotech Advisory Panel of Hong Kong Stock Exchange since April 2018. Dr. Shi obtained his doctoral degree in biophysics and master's degree in science from the University of Rochester in New York, the United States in April 1991 and January 1989 respectively, and a bachelor's degree in science from University of Science and Technology of China in China in July 1986.

Pursuant to the letters of appointment made between the Company and each of Mr. Cheung and Dr. Sh, the appointments of Mr. Cheung and Dr. Shi will be for an initial term of three years commencing from 12 April 2024. They are subject to retirement by rotation and eligible for re-election pursuant to the memorandum of association and the articles of association of the Company and the Listing Rules. Therefore, Mr. Cheung and Dr. Shi will hold office until the next annual general meeting of the Company at which they will be eligible for re-election.

Following the above-mentioned changes to the Nomination Committee, the Nomination Committee would comprise one executive director of the Company, namely Mr. Meng Jiange, and four independent non-executive Directors, namely Mr. Pan Jiuan, Mr. Dai Zumian, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang as members.